Latest Strategy News

Lakes Blue Energy reported a $1.5 million quarterly operational spend and completed the $6.5 million sale of its 49% interest in PEP 169, while progressing drilling approvals for the Wombat-5 well in Victoria.

Torque Metals delivers standout drilling results at its Paris Gold Project, confirming high-grade gold zones beyond existing resources, while bolstering its portfolio with new gold and lithium tenements and a successful $1M share placement.

Emerald Resources NL has reported record quarterly gold production at its Okvau Gold Mine, alongside significant resource expansions in Cambodia and Australia, positioning the company for robust growth.

GreenHy2 Limited reports a slight cash decline but strengthens its foothold in renewable energy with key partnerships and strategic pivots in hydrogen storage technology.

Percheron Therapeutics has terminated its phase IIb avicursen trial for Duchenne muscular dystrophy after failing to meet efficacy endpoints, while securing $14.85 million in fresh capital to explore new therapeutic opportunities.

Advance Metals Limited has significantly expanded its portfolio with binding agreements to acquire high-grade silver and gold projects in Mexico and Australia, setting the stage for an active 2025 exploration campaign.

Elixir Energy wraps up Daydream-2 well operations and prepares for next appraisal in a strengthening gas market, while progressing farmout talks for Australian and Mongolian assets.

Live Verdure Ltd has secured a controlling stake in AI innovator Decidr.ai and reported robust e-commerce growth for its Edible Beauty brand, underscoring its strategic pivot towards AI-driven expansion.

Little Green Pharma reports a robust 75% revenue increase to $9.5 million for December quarter, driven by strong European market growth and strategic product launches.

Lycaon Resources completes its first drilling program at the Stansmore Nb-REE target, revealing modest mineralization, while reinforcing its leadership with key board appointments and planned capital injections.

Telix Pharmaceuticals has completed a strategic acquisition of ImaginAb, gaining next-generation therapeutic assets and a novel biologics platform to expand its oncology pipeline and R&D capabilities.

Mach7 Technologies reports a robust Q2 FY25 with a 15.6% increase in Contracted Annual Recurring Revenue, reaffirming its FY25 growth guidance and initiating a $5 million share buy-back.